Eli Lilly and Company entered into an exclusive licensing agreement with Australia‑based CSL on February 18, 2026, to acquire U.S. and other territorial commercial rights for clazakizumab, a monoclonal antibody that targets interleukin‑6 (IL‑6) and is being developed to prevent cardiovascular events in patients with end‑stage kidney disease (ESKD).
The agreement provides Lilly with an upfront payment of $100 million and the potential for milestone payments and sales‑based royalties. CSL retains the rights to develop and commercialize clazakizumab for the prevention of cardiovascular events in ESKD, while Lilly gains rights to pursue additional indications beyond the ESKD cardiovascular program. The drug was originally developed by Vitaeris Inc. and acquired by CSL in 2020; CSL is currently advancing the POSIBIL6ESKD Phase 3 trial in ESKD patients.
Strategically, the deal expands Lilly’s presence in the nephrology and immunology spaces, complementing its strong cardiometabolic and oncology businesses. Lilly’s broader M&A strategy in early 2026—highlighted by the acquisition of Orna Therapeutics and a collaboration with Innovent Biologics—underscores its focus on immunology and cardiovascular assets. The $100 million upfront payment provides immediate cash flow, while future milestone and royalty streams could add significant long‑term revenue if clazakizumab proves successful in Phase 3.
For CSL, the licensing arrangement monetizes an asset that has faced a setback in a transplant rejection trial but remains a promising candidate for cardiovascular disease. The deal allows CSL to focus resources on its core ESKD program while securing a cash infusion and potential future upside from Lilly’s development of additional indications. The transaction also signals confidence in the IL‑6 pathway, a target pursued by other companies such as Novartis.
Market reaction to the announcement was positive for CSL, with shares rising about 2% in Wednesday trade after a 17% decline earlier in the week due to weak earnings and leadership changes. The $100 million upfront payment and the validation of clazakizumab’s potential were cited as key drivers of the recovery.
Bill Mezzanotte, EVP and Head of Research and Development at CSL, said, “This agreement marks a significant step forward in our mission to bring innovative therapies to patients worldwide. Clazakizumab is a promising therapeutic candidate with the potential to significantly impact the treatment landscape for various immuno‑inflammatory and cardiovascular conditions. Lilly is another patient‑focused organization, and we look forward to working with them to maximise the potential of this important medicine.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.